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INTRODUCTION
Clustered regularly interspaced palin-
dromic repeats (CRISPR)/Cas9 is a
gene-editing technology causing a major
upheaval in biomedical research. It makes
it possible to correct errors in the genome
and turn on or off genes in cells and organ-
isms quickly, cheaply and with relative
ease. It has a number of laboratory applica-
tions including rapid generation of cellular
and animal models, functional genomic
screens and live imaging of the cellular
genome.1 It has already been demonstrated
that it can be used to repair defective DNA
in mice curing them of genetic disorders,2
and it has been reported that human
embryos can be similarly modified.3 Other
potential clinical applications include gene
therapy, treating infectious diseases such as
HIV and engineering autologous patient
material to treat cancer and other diseases.
In this review we will give an overview of
CRISPR/Cas9 with an emphasis on how it
may impact on the specialty of paediatrics.
Although it is likely to have a significant
effect on paediatrics through its impact in
the laboratory, here we will concentrate on
its potential clinical applications. We will
also describe some of the difficulties and
ethical controversies associated with this
novel technology.
OVERVIEW OF CRISPR/CAS9
CRISPR/Cas9 is a gene-editing technology
which involves two essential components:
a guide RNA to match a desired target
gene, and Cas9 (CRISPR-associated
protein 9)—an endonuclease which causes
a double-stranded DNA break, allowing
modifications to the genome (see
figure 1).
POTENTIAL CLINICAL USES
Correction of genetic disorders
One of the most exciting applications of
CRISPR/Cas9 is its potential use to treat
genetic disorders caused by single gene
mutations. Examples of such diseases
include cystic fibrosis (CF), Duchenne’s
muscular dystrophy (DMD) and haemo-
globinopathies. The approach so far has
currently only been validated in preclin-
ical models, but there is hope it can soon
be translated to clinical practice.
Schwank et al used CRISPR/Cas9 to
investigate the treatment of CF. Using
adult intestinal stem cells obtained from
two patients with CF, they successfully
corrected the most common mutation
causing CF in intestinal organoids. They
demonstrated that once the mutation had
been corrected, the function of the CF
transmembrane conductor receptor
(CFTR) was restored.4
Another disease in which CRISPR/Cas9
has been investigated is DMD. Tabebordbar
et al recently used adeno-associated virus
(AAV) delivery of CRISPR/Cas9 endonu-
cleases to recover dystrophin expression in
a mouse model of DMD, by deletion of the
exon containing the original mutation. This
produces a truncated, but still functional
protein. Treated mice were shown to par-
tially recover muscle functional deficien-
cies.5 Significantly, it was demonstrated that
the dystrophin gene was edited in muscle
stem cells which replenish mature muscle
tissue. This is important to ensure any
therapeutic effects of CRISPR/Cas9 do not
fade over time. Two similar studies have
described using the CRISPR/Cas9 system in
vivo to increase expression of the dys-
trophin gene and improve muscle function
in mouse models of DMD.6 7 Other studies
have used CRISPR/Cas9 to target duplica-
tion of exons in the human dystrophin gene
in vitro and have shown that this approach
can lead to production of full-length dys-
trophin in the myotubules of an individual
with DMD.8
CRISPR/Cas9 could also be used to
treat haemoglobinopathies. Canver et al9
recently showed BCL11A enhancer dis-
ruption by CRISPR/Cas9 could induce
fetal haemoglobin in both mice and
primary human erythroblast cells. In the
future such an approach could allow fetal
haemoglobin to be expressed in patients
with abnormal adult haemoglobin. This
would represent a novel therapeutic strat-
egy in patients with diseases such as
sickle cell disease or thalassaemias.
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Knock-in of a fully functional β-globin gene is much
more challenging, which is the reason for this some-
what unusual approach.
Treatment of HIV
Another potential clinical application of CRISPR/Cas9
is to treat infectious diseases, such as HIV. Although
antiretroviral therapy provides an effective treatment
for HIV, no cure currently exists due to permanent
integration of the virus into the host genome. Hu et al
showed the CRISPR/Cas9 system could be used to
target HIV-1 genome activity. This inactivated HIV
gene expression and replication in a variety of cells
which can be latently infected with HIV, without any
toxic effects. Furthermore, cells could also be immu-
nised against HIV-1 infection. This is a potential thera-
peutic advance in overcoming the current problem of
how to eliminate HIV from infected individuals. After
further refinement, the authors suggest their findings
may enable gene therapies or transplantation of genet-
ically altered bone marrow stem cells or inducible
pluripotent stem cells to eradicate HIV infection.10
Engineering somatic cells ex vivo to treat malignancy
or other diseases
There has been increasing interest in the possibility of
using CRISPR/Cas9 to modify patient-derived T-cells
and stem/progenitor cells which can then be reintro-
duced into patients to treat disease. This approach
may overcome some of the issues associated with how
to efficiently deliver gene editing to the right cells.
T-cell genome engineering has already shown
success in treating haematological malignancies and
has the potential to treat solid cancers, primary
immune deficiencies and autoimmune diseases.
Genetic manipulation of T-cells has previously been
inefficient. However, Schumann et al recently
reported a more effective approach in human CD4+
T-cells based on the CRISPR/Cas9 system. Their tech-
nique allowed experimental and therapeutic knock-
out and knock-in editing of the genome in primary
human T-cells. They demonstrated T-cells could be
manipulated to prevent expression of the protein
PD-1, which other work has shown may allow T-cells
to target solid cancers.11
There is also interest in using CRISPR/
Cas9-mediated genome editing in pluripotent stem
cells or primary somatic stem cells to treat disease. For
example Xie et al12 showed the mutation causing
β-thalassaemia could be corrected in human induced
pluripotent stem cells ex vivo. They suggest that in
the future such an approach could provide a source of
cells for bone marrow transplantation to treat
β-thalassaemia and other similar monogenic diseases.
LIMITATIONS
A number of challenges remain before the potential of
CRISPR/Cas9 can be translated to effective treatments
at the bedside. A particular issue is how to deliver
gene editing to the right cells, especially if the treat-
ment is to be delivered in vivo. To safely deliver
Cas9-nuclease encoding genes and guide RNAs in
vivo without any associated toxicity, a suitable vector
is needed. AAV has previously been a favoured option
for gene delivery.1 However, this delivery system may
be too small to allow efficient transduction of the
Cas9 gene.1 A smaller Cas9 gene could be used, but
this has additional implications on efficacy.1 A number
of other non-viral delivery systems are under investi-
gation and this process requires further optimisation.
Another significant concern is the possibility of off-
target effects on parts of the genome separate from
the region being targeted. Unintentional edits of the
genome could have profound long-term complications
for patients, including malignancy. The concentration
of the Cas9 nuclease enzyme and the length of time
Cas9 is expressed are both important when limiting
off-target activity.1 Although recent modifications in
the nuclease have increased specificity, further work is
required to minimise off-target effects and to establish
the long-term safety of any treatment.
The therapeutic applications of CRISPR/Cas9 con-
sidered in this article have predominantly been direc-
ted at somatic cells. A particularly controversial issue
surrounding CRISPR/Cas9 is that of gene editing in
Figure 1 The CRISPR/Cas9 system.1 Clustered regularly
interspaced palindromic repeats (CRISPR) refers to sequences in
the bacterial genome. They afford protection against invading
viruses, when combined with a series of CRISPR-associated
(Cas) proteins. Cas9, one of the associated proteins, is an
endonuclease that cuts both strands of DNA. Cas9 is directed to
its target by a section of RNA. This can be synthesised as a
single strand called a synthetic single guide RNA (sgRNA); the
section of RNA which binds to the genomic DNA is 18–20
nucleotides. In order to cut, a specific sequence of DNA of
between 2 and 5 nucleotides (the exact sequence depends
upon the bacteria which produces the Cas9) must lie at the 3’
end of the guide RNA: this is called the protospacer adjacent
motif (PAM). Repair after the DNA cut may occur via two
pathways: non-homologous end joining, typically leading to a
random insertion/deletion of DNA, or homology directed repair
where a homologous piece of DNA is used as a repair template.
It is the latter which allows precise genome editing: the
homologous section of DNA with the required sequence change
may be delivered with the Cas9 nuclease and sgRNA,
theoretically allowing changes as precise as a single base-pair.
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embryos. It has already been shown that CRISPR/
Cas9 technology can alter the genome of human
embryos3 which theoretically could prove useful in
the preimplantation treatment of genetic diseases.
However, any genetic modification of the germline
would be permanent and the long-term consequences
are unclear. Many oppose germline modification
under any circumstances, reasoning that an eventual
consequence could be non-therapeutic genetic
enhancement.13 It is clear that the ethical boundaries,
within which CRISPR/Cas9 can be used, remain to be
fully determined.
Clinical bottom line
▸ CRISPR/Cas9 technology has the potential to revolu-
tionise the treatment of many paediatric conditions.
▸ A number of practical and ethical challenges must be
overcome before this potential can be realised at the
bedside.
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